ArticleClinical and translational allergy2026
Utility of Patch Testing, LTT, and HLA Genotyping in Identifying Culprit Drugs and Diagnosing Multiple Drug Hypersensitivity in Definite DRESS: A 10-Year Cohort Study.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimWe evaluated the role of lymphocyte transformation test (LTT), patch testing (PT), and human leukocyte antigen (HLA) genotyping in identifying culprit drugs in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and assessed long-term outcomes.
methodsDRESS was diagnosed using Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria; only definite cases (score > 5) were included. Severe DRESS was defined as ≥ 1 major organ involvement with clinical and laboratory abnormalities, and RegiSCAR scores supported severity assessment. Patients were grouped by single- or multiple drug exposure. Drug causality was assessed using the WHO-UMC criteria. LTT, PT, and/or HLA genotyping were performed for "possible" culprit drugs. Multiple drug hypersensitivity syndrome (MDHS) was defined as hypersensitivity to ≥ 2 unrelated drugs confirmed by testing. Hypersensitivity to a single drug was classified as single-drug hypersensitivity (SDH). Long-term follow-up assessed autoimmune diseases and neo-sensitization to unrelated drugs.
resultsFifty patients with definite DRESS (median age 49 years; 50% were female) were included, and six (12%) had severe disease. Compared with non-severe cases (mild/moderate), severe cases had higher median RegiSCAR scores (8 [7-8] vs. 6 [6-7]; p = 0.012) and more frequent facial edema (p < 0.001) and lymphadenopathy (p = 0.029). MDHS was more common in severe cases (83% vs. 11%; p = 0.001), and HLA risk alleles were more prevalent (p = 0.016), including HLA-B*58:01, HLA-A*31:01, and HLA-B*13:02, associated with allopurinol, carbamazepine, and levofloxacin-induced DRESS, respectively. Among 20 patients with multiple drug exposures, 10 were diagnosed with MDHS: 5 simultaneous, 2 sequential, and 4 long-interval; one patient exhibited both simultaneous and long-interval reactions. Compared with SDH, MDHS patients had higher median RegiSCAR scores (7 [6-8] vs. 6 [6-8]; p < 0.001) and a higher prevalence of HLA risk alleles (p = 0.038), including HLA-B*58:01 (allopurinol), HLA-A*31:01 (carbamazepine), HLA-B*13:02 (levofloxacin) and HLA-A*24:02 (lamotrigine). Long-term complications occurred in eight patients: four developed autoimmune diseases, and four had neo-sensitization leading to subsequent DRESS, considered long-interval MDHS.
conclusionPT and LTT effectively identified culprit drugs in DRESS, particularly in multiple drug exposure. MDHS was more frequent in severe DRESS and associated with a higher prevalence of drug-related HLA risk alleles; however, no single HLA marker defined MDHS. Long-term follow-up was essential to detect autoimmune sequelae and neo-sensitization, and to guide safe drug evaluation and reintroduction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.